Abeona Therapeutics Announces 2026 Annual Meeting Results and Director Elections

Abeona Therapeutics Inc. held its annual meeting of stockholders on June 12, 2026, where several key proposals were voted upon. Stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors to serve until the 2029 annual meeting. Additionally, shareholders approved the advisory compensation for named executive officers and ratified Deloitte & Touche LLP as the company\'s independent registered public accounting firm for the fiscal year ending December 31, 2026. A significant proposal to increase the number of shares reserved for issuance under the Second Amended and Restated 2023 Equity Incentive Plan from 8,400,000 to 11,500,000 was also approved. However, a proposal to amend the Company’s Certificate of Incorporation to remove the advance notice provision for director nominations failed to pass, as it did not receive the required 66 2/3% affirmative vote from outstanding shares. The meeting results reflect strong support for the current board and executive compensation, while maintaining existing corporate governance provisions regarding director nominations.